Circadia Health

Circadia Health develops contactless patient monitoring tools that combine hardware, artificial intelligence and software to predict medical events and reduce rehospitalisations in post-acute care. The company builds its systems in-house across radar sensing and RF vital-sign detection, machine learning, predictive analytics, hardware engineering, clinical software platforms and care-coordination technology. Its staff is a multidisciplinary team of engineers, scientists and physicians, and the firm describes its culture as one of challenging established practice to set new standards of care, with an emphasis on asking the right questions and solving the right problems.

The company's flagship product, the Circadia C200, uses radar to capture vital signs without touching the patient. It is described as the world's first FDA-cleared contactless patient monitoring system and detects early signs of heart failure, pneumonia and sepsis. The Clinical Intelligence Platform turns patient data into clinical insights, and accompanying care-coordination services close the loop on care delivery. The underlying philosophy is monitoring without wearables.

Circadia reports that more than 30,000 patients are monitored daily on its systems and that rehospitalisations fell by 30% after 12 months of use. The company operates in the healthcare, medical-device, hospital and post-acute-care sectors. Further details on founding year, team size, funding and geographic presence are not published.